IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer
Comparison
Peer Comparison Report
Performance
Performance Report
Akums Drugs and Pharmaceuticals
IPO is a MainBoard IPO coming on
BSE,NSE with an
IPO
size of
1856.74 Cr..
This IPO falls under the
Pharmaceutical sector, which has seen
57 IPOs
to date. Key sector metrics such as average PE ratio, IPO size, EBITDA margin, and
PAT margin are compared below with the figures from the
Akums Drugs and Pharmaceuticals
IPO.
You can do performance analysis for Akums Drugs IPO with Listed IPOs in the Pharmaceutical sector and review their IPO performance based on Merchant banker, Listing price, IPO Valuation and other metrics.
This IPO report captures the post-listing performance of IPOs in the Pharmaceutical sector, featuring key metrics like offer price, listing gain, and CMP to help investors assess return potential and sector sentiment.
| NAME | TYPE | OFFER PRICE | LISTING PRICE | LISTING GAIN | CMP | CMP % |
|---|---|---|---|---|---|---|
|
Astonea Labs
IPO
Financial Report >> |
SME | ₹ 135.00 | ₹ 137.45 | 1.81% | ₹ 146.75 | 9% |
|
Accretion Pharmaceuticals
IPO
Financial Report >> |
SME | ₹ 101.00 | ₹ 79.00 | -21.78% | ₹ 69.35 | -31% |
|
Senores Pharmaceuticals
IPO
Financial Report >> |
MainBoard | ₹ 391.00 | ₹ 609.00 | 55.75% | ₹ 573.00 | 47% |
|
Hamps Bio
IPO
Financial Report >> |
SME | ₹ 51.00 | ₹ 101.74 | 99.49% | ₹ 40.99 | -20% |
|
Onyx Biotec
IPO
Financial Report >> |
SME | ₹ 61.00 | ₹ 56.75 | -6.97% | ₹ 52.40 | -14% |
|
Emcure Pharmaceuticals
IPO
Financial Report >> |
MainBoard | ₹ 1008.00 | ₹ 1358.85 | 34.81% | ₹ 1318.40 | 31% |
|
Medicamen Organics
IPO
Financial Report >> |
SME | ₹ 34.00 | ₹ 144.70 | 325.59% | ₹ 45.95 | 35% |
|
Quest Laboratories
IPO
Financial Report >> |
SME | ₹ 97.00 | ₹ 147.35 | 51.91% | ₹ 85.55 | -12% |
|
Indegene Limited
IPO
Financial Report >> |
MainBoard | ₹ 452.00 | ₹ 570.65 | 26.25% | ₹ 574.65 | 27% |
|
Zenith Drugs
IPO
Financial Report >> |
SME | ₹ 79.00 | ₹ 105.15 | 33.10% | ₹ 68.90 | -13% |
|
Innova Captab
IPO
Financial Report >> |
MainBoard | ₹ 448.00 | ₹ 545.15 | 21.69% | ₹ 853.80 | 91% |
|
Sunrest Lifescience
IPO
Financial Report >> |
SME | ₹ 84.00 | ₹ 79.80 | -5.00% | ₹ 52.00 | -38% |
|
Blue Jet
IPO
Financial Report >> |
MainBoard | ₹ 346.00 | ₹ 395.85 | 14.41% | ₹ 869.65 | 151% |
|
Valiant Laboratories
IPO
Financial Report >> |
MainBoard | ₹ 140.00 | ₹ 169.05 | 20.75% | ₹ 113.81 | -19% |
|
Mono Pharmacare
IPO
Financial Report >> |
SME | ₹ 28.00 | ₹ 30.45 | 8.75% | ₹ 24.50 | -13% |
|
Concord Biotech
IPO
Financial Report >> |
MainBoard | ₹ 741.00 | ₹ 941.85 | 27.11% | ₹ 1798.60 | 143% |
|
Vilin Bio
IPO
Financial Report >> |
SME | ₹ 30.00 | ₹ 30.00 | [●] | ₹ 27.85 | -7% |
|
Remus Pharmaceuticals
IPO
Financial Report >> |
SME | ₹ 1229.00 | ₹ 1711.00 | 39.22% | ₹ 1959.45 | 59% |
|
Mankind Pharma
IPO
Financial Report >> |
MainBoard | ₹ 1080.00 | ₹ 1424.05 | 31.86% | ₹ 2303.50 | 113% |
|
Infinium Pharmachem
IPO
Financial Report >> |
SME | ₹ 135.00 | ₹ 141.50 | 4.81% | ₹ 296.65 | 120% |
|
Sotac Pharmaceuticals
IPO
Financial Report >> |
SME | ₹ 111.00 | ₹ 115.00 | 3.60% | ₹ 131.65 | 19% |
|
Sudarshan Pharma
IPO
Financial Report >> |
SME | ₹ 73.00 | ₹ 73.00 | [●] | ₹ 26.56 | -64% |
|
Patron Exim
IPO
Financial Report >> |
SME | ₹ 27.00 | ₹ 28.40 | 5.19% | ₹ 6.10 | -77% |
|
Trident Lifeline
IPO
Financial Report >> |
SME | ₹ 101.00 | ₹ 108.15 | 7.08% | ₹ 272.40 | 170% |
|
JFL Life
IPO
Financial Report >> |
SME | ₹ 61.00 | ₹ 66.50 | 9.02% | ₹ 15.05 | -75% |
|
Dipna Pharmachem
IPO
Financial Report >> |
SME | ₹ 38.00 | ₹ 33.40 | -12.11% | ₹ 22.64 | -40% |
|
Achyut Healthcare
IPO
Financial Report >> |
SME | ₹ 20.00 | ₹ 21.15 | 5.75% | ₹ 3.54 | -82% |
|
Evoq Remedies
IPO
Financial Report >> |
SME | ₹ 27.00 | ₹ 23.75 | -12.04% | ₹ 5.55 | -79% |
|
Fabino Life
IPO
Financial Report >> |
SME | ₹ 36.00 | ₹ 40.35 | 12.08% | ₹ 30.80 | -14% |
|
Supriya Lifescience
IPO
Financial Report >> |
MainBoard | [●] | ₹ 390.35 | 42.46% | ₹ 680.60 | 148% |
|
Medplus Health
IPO
Financial Report >> |
MainBoard | [●] | ₹ 1120.85 | 40.81% | ₹ 903.00 | 13% |
|
Windlas Biotech
IPO
Financial Report >> |
MainBoard | [●] | ₹ 406.70 | 406.70% | ₹ 895.10 | 95% |
|
Glenmark Life
IPO
Financial Report >> |
MainBoard | [●] | ₹ 748.20 | 748.20% | ₹ 994.60 | 38% |
|
Gland Pharma
IPO
Financial Report >> |
MainBoard | [●] | ₹ 1820.45 | 1820.45% | ₹ 1792.30 | 19% |
|
Chandra Bhagat
IPO
Financial Report >> |
SME | ₹ 51.00 | ₹ 51.76 | 1.49% | ₹ 58.00 | 14% |
|
Earum Pharmaceuticals
IPO
Financial Report >> |
SME | ₹ 36.00 | ₹ 36.05 | 0.14% | ₹ 1.07 | -97% |
|
Cian Healthcare
IPO
Financial Report >> |
SME | ₹ 61.00 | ₹ 61.50 | 0.82% | ₹ 4.21 | -93% |
|
Par Drugs
IPO
Financial Report >> |
SME | ₹ 51.00 | ₹ 51.45 | 0.88% | ₹ 95.21 | 87% |
|
Deccan Health
IPO
Financial Report >> |
SME | ₹ 100.00 | ₹ 113.40 | 13.40% | ₹ 19.47 | -81% |
|
Medico Remedies
IPO
Financial Report >> |
SME | ₹ 100.00 | ₹ 97.15 | -2.85% | ₹ 49.00 | 145% |
|
Beta Drugs
IPO
Financial Report >> |
SME | [●] | ₹ 101.95 | 19.94% | ₹ 1765.00 | 1976% |
|
Vanta Bioscience
IPO
Financial Report >> |
SME | [●] | ₹ 50.20 | 0.40% | ₹ 27.32 | -45% |
|
Dhruv Wellness
IPO
Financial Report >> |
SME | [●] | ₹ 19.50 | -2.50% | ₹ 5.32 | -73% |
|
ANG Lifesciences
IPO
Financial Report >> |
SME | [●] | ₹ 96.00 | 20.00% | ₹ 27.83 | -65% |
|
Vaishali Pharma
IPO
Financial Report >> |
SME | [●] | ₹ 70.35 | -2.29% | ₹ 11.86 | -18% |
|
Eris Lifesciences
IPO
Financial Report >> |
MainBoard | [●] | ₹ 601.05 | 601.05% | ₹ 1618.00 | 168% |
|
Zota Health
IPO
Financial Report >> |
SME | [●] | ₹ 125.60 | 0.48% | ₹ 942.75 | 654% |
|
Laurus Labs
IPO
Financial Report >> |
MainBoard | [●] | ₹ 480.50 | 480.50% | ₹ 680.35 | 695% |
|
Sakar Healthcare
IPO
Financial Report >> |
SME | [●] | ₹ 52.15 | 4.30% | ₹ 366.00 | 632% |
|
Kwality Pharmaceuticals
IPO
Financial Report >> |
SME | [●] | ₹ 44.50 | -1.11% | ₹ 1024.90 | 2178% |
|
Bajaj Healthcare
IPO
Financial Report >> |
SME | [●] | ₹ 171.50 | 0.88% | ₹ 523.30 | 2978% |
|
Alkem Laboratories
IPO
Financial Report >> |
MainBoard | [●] | ₹ 1381.45 | 1381.45% | ₹ 4841.00 | 361% |
|
Syngene International
IPO
Financial Report >> |
MainBoard | [●] | ₹ 310.40 | 310.40% | ₹ 645.70 | 158% |
|
Brooks Laboratories
IPO
Financial Report >> |
MainBoard | [●] | ₹ 60.20 | -39.80% | ₹ 150.00 | 50% |
|
Parabolic Drugs
IPO
Financial Report >> |
MainBoard | [●] | ₹ 64.80 | 64.80% | [●] | [●] |
|
Bafna Pharmaceuticals
IPO
Financial Report >> |
MainBoard | [●] | ₹ 38.50 | 38.50% | [●] | [●] |
|
SMS Pharmaceuticals
IPO
Financial Report >> |
MainBoard | [●] | ₹ 357.85 | 357.85% | ₹ 247.70 | 552% |
Akums Drugs and Pharmaceuticals IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
Akums Drugs and Pharmaceuticals IPO, based in New Delhi, operates in the Pharmaceutical sector with a focus on Pharmaceuticals. The company is launching its MainBoard IPO on the BSE,NSE exchange, using the Book Building Issue method. Akums Drugs and Pharmaceuticals IPO size is ₹ 1856.74 Cr. with fresh issue size of ₹ 680.00 Cr. and Offer for sale being ₹ 1176.74Cr.
The IPO allotment date for Akums Drugs and Pharmaceuticals IPO is expected to be 2nd August 2024, after the finalization of basis of allotment. Investors can check Akums Drugs and Pharmaceuticals IPO allotment status on the registrars website, Link Intime India Private Limited . Akums Drugs and Pharmaceuticals IPO refund dates are 5th August 2024.
Akums Drugs and Pharmaceuticals IPO is expected to be listed on 6th August 2024.
The upper price band for the Akums Drugs and Pharmaceuticals IPO is set at ₹ 679.00 per equity share. IPO price band is arrived at on the basis of IPO Valuation (P/E multiple) which is mentioned in the RHP.
For IPO analysis on Akums Drugs and Pharmaceuticals IPO, explore our Financial Review Page for insights on fundamentals, peer analysis, and key IPO data, assisting investors to make informed decisions to apply or not.
To apply for the Akums Drugs and Pharmaceuticals IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of 1st August 2024. After submission, funds are blocked until the basis of allotment of Akums Drugs and Pharmaceuticals IPO is finalised.
The merchant banker for Akums Drugs and Pharmaceuticals IPO is Ambit Private Limited , Axis Bank Limited , Citigroup Global Markets India Private Limited , ICICI Securities Limited . Ambit Private Limited , Axis Bank Limited , Citigroup Global Markets India Private Limited , ICICI Securities Limited manages the IPO process, including underwriting, regulatory compliance, and investor coordination. Investors can refer to the Akums Drugs and Pharmaceuticals IPO RHP for further details.
The registrar for Akums Drugs and Pharmaceuticals IPO is Link Intime India Private Limited . Investors can go to Link Intime India Private Limited registrar website for IPO allotment status, refund processing, and other queries related to Akums Drugs and Pharmaceuticals IPO through their official website or helpline.
Akums Drugs and Pharmaceuticals IPO was subscribed 63.44 times. Stay updated on IPO details, subscription, and allotment news for informed investment decisions.
Why Us?
